KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Deferred Revenue: 2019-2024

Historic Current Deferred Revenue for Esperion Therapeutics (ESPR) over the last 6 years, with Dec 2024 value amounting to $8.5 million.

  • Esperion Therapeutics' Current Deferred Revenue rose 103.47% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year increase of 103.47%. This contributed to the annual value of $8.5 million for FY2024, which is 66.47% down from last year.
  • Per Esperion Therapeutics' latest filing, its Current Deferred Revenue stood at $8.5 million for FY2024, which was down 66.47% from $25.4 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Current Deferred Revenue registered a high of $25.4 million during FY2023, and its lowest value of $1.7 million during FY2020.
  • Over the past 3 years, Esperion Therapeutics' median Current Deferred Revenue value was $8.5 million (recorded in 2024), while the average stood at $12.5 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Current Deferred Revenue spiked by 624.32% in 2023, and later tumbled by 66.47% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Current Deferred Revenue (Yearly) stood at $1.7 million in 2020, then spiked by 241.94% to $5.7 million in 2021, then plummeted by 38.29% to $3.5 million in 2022, then surged by 624.32% to $25.4 million in 2023, then crashed by 66.47% to $8.5 million in 2024.